Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical company focused on allergy and autoimmune conditions, closed a $98M Series D financing. Participants include Imperial Innovations and Invesco Perpetual.

PolyTherics (United Kingdom) a clinical-stage protein engineering company focused on site-specific PEGylation of biologics, closed a $4M Series C financing. Participants include Imperial Innovations, Longbow Capital and The Capital Fund.

Veryan (United Kingdom) a clinical-stage medical device company focused on a three dimensional vascular stent for peripheral vascular disease, closed a $5.4M series B financing. Participants include Seroba Kernal, Imperial Innovations, Oxford Capital Partners and NESTA.

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

BioCeramic Therapeutics (United Kingdom) a development-stage provider of bioactive materials for orthopaedic and dental applications, closed a $1.9M Series B financing. Participants include Imperial Innovations, Longbow Capital Partners, Comvest and Esmee Fairbairn Foundation.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

BioCeramic Therapeutics (United Kingdom) a development-stage provider of bioactive materials for orthopaedic and dental applications, closed a $1.9M Series B financing. Participants include Imperial Innovations, Longbow Capital Partners, Comvest and Esmee Fairbairn Foundation.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.